What is Molecular Partners AG Book Value per Share?
Molecular Partners AG's book value per share for the quarter that ended in Mar. 2024 was CHF5.13.
During the past 12 months, Molecular Partners AG's average Book Value Per Share Growth Rate was -24.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 13.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 11.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -1.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Molecular Partners AG was 38.30% per year. The lowest was -27.40% per year. And the median was -9.00% per year.
During the past 11 years, the highest P/B Ratio of Molecular Partners AG was 8.43. The lowest was 0.51. And the median was 0.86.
Molecular Partners AG Book Value per Share Historical Data
The historical data trend for Molecular Partners AG's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Molecular Partners AG's Book Value per Share
For the Biotechnology subindustry, Molecular Partners AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecular Partners AG's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecular Partners AG's PB Ratio distribution charts can be found below:
* The bar in red indicates where Molecular Partners AG's PB Ratio falls into.
Molecular Partners AG Book Value per Share Calculation
Molecular Partners AG's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Molecular Partners AG (XSWX:MOLN) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Molecular Partners AG Book Value per Share Related Terms
Thank you for viewing the detailed overview of Molecular Partners AG's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Molecular Partners AG (XSWX:MOLN) Business Description
Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XSWX:MOLN has been successfully added to your 